Publications
Links to our latest financial and sustainability reports and other recent publications.
该网页正在调整中,因此,无法以您所使用的语言显示所有内容。
对于给您带来的不便,我们深表歉意。
Grifols’ fourth quarter and year-end 2024 results.
Showing 225 search results
Grifols partners with IBL International to develop advanced biomarker panels for unique clinical diagnostics platform
Grifols appoints Montse Ribas as Chief Communications and Reputation Officer to strengthen the company's global reputation
Grifols and Inpeco joining forces to deliver transfusion medicine ‘lab of the future’
Grifols Phase 2/3 trial shows positive impact of immunoglobulin therapy on post-polio patients
Grifols expects to reach EUR 10 billion in revenue, EUR 2.9 billion in EBITDA and EUR 3.5+ billion in cumulative cash flow by 2029
Grifols delivers a strong 2024 exceeding guidance on revenue and free cash flow
Links to our latest financial and sustainability reports and other recent publications.
Financial Report
Explore our last financial and earnings report.
Sustainability Report
Integrated and Sustainability Annual Report.
Position Paper
The differential value of plasma-derived medicinal products (PDMPs).
Press Kit
Explore our Press Kit to find key facts and figures on Grifols.
If you're a journalist or media professional with a question, contact our media relations team.